{"entity":{"id":"ct3001","kind":"drug","name":"CT3001","aka":[],"tldr":"CT3001 is a small-molecule inhibitor from Crossignal Therapeutics, Inc., in registered phase 2 trials for colorectal cancer, pancreatic ductal adenocarcinoma.","summary":"CT3001 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Crossignal Therapeutics, Inc., in colorectal cancer, pancreatic ductal adenocarcinoma. Described in the registry record as a a small molecule inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of CT3001","url":"https://clinicaltrials.gov/search?intr=CT3001"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["colorectal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06598007"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"CT3001","modality":"Small-molecule inhibitor","mechanism":"Described in the registry record as a a small molecule inhibitor; the trial entries below carry the sponsor's wording.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ct3001/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"trial":[{"id":"nct06598007","kind":"trial","name":"A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors","route":"/trials/nct06598007/"}]}}